ACXP · Acurx Pharmaceuticals Inc
United States · RS rating 6 · As of 2026-10-14
| Price | 1.15 USD |
|---|---|
| 1-day change | -4.2% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 16 / 13 / 5 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 16 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +14.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +84.8% |
| Market cap (USD) | $5.7M |